<div id="readability-page-1"><p>Nuveen Asset Management LLC decreased its stake in  PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 38.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 153,802 shares of the company's stock after selling 94,827 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.29% of PROCEPT BioRobotics worth $12,384,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>PROCEPT BioRobotics</strong> alerts:</span></p></div><ul><li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li></ul><p>Several other institutional investors have also modified their holdings of PRCT. FMR LLC grew its position in shares of  PROCEPT BioRobotics by 11.9% in the fourth quarter. FMR LLC now owns 8,159,208 shares of the company's stock valued at $656,979,000 after purchasing an additional 866,328 shares during the period.  Wellington Management Group LLP lifted its stake in shares of  PROCEPT BioRobotics by 38.8% in the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock worth $120,051,000 after buying an additional 416,819 shares in the last quarter.  Vanguard Group Inc. lifted its stake in shares of  PROCEPT BioRobotics by 6.1% in the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock worth $413,907,000 after buying an additional 297,075 shares in the last quarter.  Renaissance Technologies LLC purchased a new position in shares of  PROCEPT BioRobotics in the fourth quarter worth about $22,422,000.  Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of  PROCEPT BioRobotics by 218.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 401,210 shares of the company's stock worth $33,350,000 after buying an additional 275,071 shares in the last quarter. Institutional investors and hedge funds own  89.46% of the company's stock. </p><h2>Insider Activity</h2><p>In related news, CFO Kevin Waters sold 733 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the sale, the chief financial officer now directly owns 107,991 shares of the company's stock, valued at $6,161,966.46. This represents a 0.67% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the sale, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20. The trade was a 3.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,455 shares of company stock valued at $368,322. Company insiders own  6.60% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>Why Intuitive Surgical Stock is Dominating the Medical Sector</li></ul><p>Several equities analysts have recently weighed in on the stock. Truist Financial decreased their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, April 11th. Bank of America decreased their price target on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, April 25th. Wall Street Zen raised shares of PROCEPT BioRobotics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday. Finally, Morgan Stanley decreased their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an &#34;overweight&#34; rating on the stock in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and six have assigned  a buy rating to the stock. Based on data from MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $90.00.</p><p><b>Check Out Our Latest Report on PROCEPT BioRobotics</b></p><h2>PROCEPT BioRobotics Stock Performance</h2><p>NASDAQ:PRCT opened at $57.38 on Tuesday. The company's 50-day moving average is $55.27 and its two-hundred day moving average is $70.16. The firm has a market capitalization of $3.17 billion, a price-to-earnings ratio of -29.43 and a beta of 1.10. PROCEPT BioRobotics Co. has a 1-year low of $47.04 and a 1-year high of $103.81. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. </p><p>PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. The business had revenue of $69.16 million for the quarter, compared to the consensus estimate of $65.39 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business's revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.51) EPS.  Analysts forecast that  PROCEPT BioRobotics Co. will post -1.75 EPS for the current year. </p><h2>About PROCEPT BioRobotics</h2> (Free Report)<p>PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than PROCEPT BioRobotics</li><li>How to Calculate Inflation Rate</li><li>Workday Stock Price Implosion: An Automatic Buy for AI Investors</li><li>What Are the FAANG Stocks and Are They Good Investments?</li><li>MercadoLibre Is Soaring—Should You Wait for a Better Entry?</li><li>How to Use the MarketBeat Excel Dividend Calculator</li><li>Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and Doubt</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in PROCEPT BioRobotics Right Now?</h2><p>Before you consider PROCEPT BioRobotics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.</p><p>While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PRCT

<p>Nuveen Asset Management LLC reduced its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 38.1% in Q4, now holding 153,802 shares valued at $12.38 million. Other institutional investors, including FMR LLC and Wellington Management, increased their stakes. Insider sales included CFO Kevin Waters and CEO Reza Zadno selling shares. Analysts have mixed ratings, with price targets ranging from $70 to $95. The stock opened at $57.38, with a market cap of $3.17 billion and a consensus rating of "Moderate Buy."</p>

PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Sold by Nuveen Asset Management LLC